Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02141542
Recruitment Status : Active, not recruiting
First Posted : May 19, 2014
Last Update Posted : October 17, 2018
MedImmune LLC
Information provided by (Responsible Party):
F. Stephen Hodi, MD, Dana-Farber Cancer Institute

Brief Summary:
This is an open label, phase I trial, testing the combination of Tremelimumab and MEDI3617 in patients with metastatic melanoma.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: Tremelimumab Drug: MEDI3617 Phase 1

Detailed Description:

Description Patients who fulfill eligibility criteria will be entered into the trial to receive tremelimumab and MEDI3617.

After the screening procedures confirm participation in the research study:

The participant will be given a study drug-dosing calendar for each treatment cycle. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have melanoma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.

  • Tremelimumab
  • MEDI3617

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Study Start Date : May 2014
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: Tremelimumab and MEDI3617
  • Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
  • Tremelimumab-Fixed doses of Tremelimumab are given once per cycle
  • MEDI3617-MEDI3617 is administered twice per cycle
Drug: Tremelimumab
Other Names:
  • CP-675,206
  • Ticilimumab

Drug: MEDI3617
Other Name: MEDI-3617

Primary Outcome Measures :
  1. Determination of the maximum tolerated dose (MTD) of the combination of tremelimumab and MEDI3617 [ Time Frame: 2 Years ]
    Determination of the maximum tolerated dose (MTD) of the combination of tremelimumab and MEDI3617

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 1 Year ]
    Overall Survival-6 month and 1 Year

  2. Overall Response Rate [ Time Frame: 12 Months ]
  3. Disease Control Rate [ Time Frame: 2 years ]
  4. Time to Tumor Progression [ Time Frame: 2 Years ]
  5. Duration of Response [ Time Frame: 2 Years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participants must meet the following criteria on screening examination to be eligible to participate in the study:
  • Participants must have histologically confirmed melanoma that is metastatic or unresectable;
  • Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan. See section 10 for the evaluation of measureable disease;
  • At least 4 weeks since prior treatment (chemotherapy, radiation therapy, hormonal therapy);
  • Age ≥18 years;
  • Life expectancy of greater than 12 weeks;
  • ECOG performance status 0-1
  • Recovered from all toxicities associated with prior treatment, to acceptable baseline status (as to Lab toxicity see below limits for inclusion) or a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4, Grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia or vitiligo
  • Participants must have adequate bone marrow, hepatic, and renal function determined within 14 days defined as:

    • Platelet count ≥ 100,000/mm3
    • Absolute neutrophil count ≥1,000/mm3
    • Hemoglobin ≥ 9 g/dL
    • Total bilirubin ≤ 1.5 x ULN (upper limit of normal) except subjects with documented Gilbert's syndrome (>5 x ULN) or liver metastasis, who must have a baseline total bilirubin ≤ 3.0 mg/dL
    • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN (≤5 x ULN if documented liver metastases are present)
    • Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance ≥ 50 mL/min as determined by the Cockcroft-Gault equation;
    • INR <1.1 X institutional upper limit of normal
  • Negative screening test results for human immunodeficiency virus (HIV), hepatitis B and C. If positive results are not indicative of true active or chronic infection, the subjects can enter the study after discussion with the Principal Investigator.
  • Females of childbearing potential who are sexually active with a non-sterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 180 days after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. They must also refrain from egg cell donation for 180 days after the final dose of investigational product.

    • Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause);
    • A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly.
  • Non-sterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Days 1 through 90 post last dose. In addition, they must refrain from sperm donation for 90 days after the final dose of investigational product;
  • Highly Effective Methods of Contraception

    • Barrier Methods

      • Male condom with spermicide
      • Copper T intrauterine device
      • Levonorgesterel-releasing intrauterine system (eg, Mirena®)( This is also considered a hormonal method)
    • Hormonal Methods

      • Implants
      • Hormone shot or injection
      • Combined pill
      • Minipill
      • Patch

Exclusion Criteria:

  • Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study.
  • Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier;
  • Received any prior monoclonal antibody against CTLA-4;
  • Any prior ≥ Grade 3 immune-related adverse event (irAE) while receiving immunotherapy or any unresolved irAE at time of study entry
  • Participants with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product;
  • The last dose of prior systemic therapy (e.g. chemotherapy, targeted therapy etc) or radiation therapy (with the exception of palliative radiotherapy) was received less than 14 days prior to the first day of treatment;
  • Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion);
  • Currently receiving systemic corticosteroids or other immunosuppressive medications or has a medical condition that requires the chronic use of corticosteroids. Note: inhaled and topical steroids are permitted;
  • Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment;
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results;
  • Active, untreated central nervous system (CNS) metastasis (subjects with brain metastases who are identified at screening may be rescreened after the lesion[s] have been appropriately treated and subjects are off corticosteroids);
  • Any serious uncontrolled medical disorder or active infection that would impair the subject's ability to receive investigational product, such as conditions associated with frequent diarrhea;
  • History of of chronic inflammatory or autoimmune disease (eg, Addison's disease, multiple sclerosis, Graves' disease, Hashimoto's thyroiditis, rheumatoid arthritis, hypophysitis, uveitis, etc) with symptomatic disease within the last 3 years. Note: Active vitiligo or alopecia or a history of vitiligo or alopecia will not be a basis for exclusion;
  • Active or history of inflammatory bowel disease (eg, colitis, Crohn's), irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Active or history of systemic lupus erythematosis or Wegener's granulomatosis;
  • History of sarcoidosis syndrome;
  • Active history of diverticulitis. Note that diverticulosis is permitted;
  • History of other malignancy unless the subject has been disease-free for at least 3 years. Non-invasive cancer history (such as carcinoma in situ [CIS] that has been resected) is allowed;
  • Unresolved toxicities from prior anticancer therapy that have not resolved to CTCAE, version 4.0, Grade ≤ 1 or baseline, with the exception of alopecia and laboratory values listed in 3.1.8;
  • Any condition that would prohibit the understanding or rendering of information and consent and compliance with the requirements of this protocol;
  • Prior treatment with angiopoietin inhibitors, or inhibitors of Tie1 or Tie2 including, but not limited to, AMG386, CVX-060, XL880, and XL820;
  • Current necessity for full-dose anticoagulation with warfarin or its equivalent (i.e. unfractionated and/or low molecular weight heparin);
  • Symptomatic peripheral vascular disease;
  • Known bleeding diathesis or coagulopathy;
  • Significant known vascular disease (e.g aortic aneurysm, aortic dissection);
  • Pulmonary hemorrhage or gross hemoptysis (bright red blood of ≥ ½ teaspoon per episode) within 6 months prior to enrollment;
  • Serious non-healing wound, ulcer, or bone fracture within 6 months prior to enrollment;
  • Major surgical procedure or significant traumatic injury within 28 days prior to study enrollment;
  • Pregnant women are excluded from this study because tremelimumab and MEDI3617 are monoclonal antibodies with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with because tremelimumab and MEDI3617, breastfeeding should be discontinued if the mother is treated with tremelimumab and MEDI3617. These potential risks may also apply to other agents used in this study.
  • Patients with grade 2 or higher peripheral neuropathy will be excluded in the dose-escalation phase of the protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02141542

United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
F. Stephen Hodi, MD
MedImmune LLC
Principal Investigator: Patrick Ott, MD Dana-Farber Cancer Institute

Responsible Party: F. Stephen Hodi, MD, Sponsor-Investigator, Dana-Farber Cancer Institute Identifier: NCT02141542     History of Changes
Other Study ID Numbers: 13-613
First Posted: May 19, 2014    Key Record Dates
Last Update Posted: October 17, 2018
Last Verified: October 2018

Keywords provided by F. Stephen Hodi, MD, Dana-Farber Cancer Institute:
Metastatic Melanoma

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs